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Introduction

Cytotoxic CD8
1 T cells scan peptides displayed by human leucocyte antigen class I (HLA-I) molecules at the cell surface. This mechanism allows T cells to kill cells that are infected with pathogens or that show dysregulation of their normal gene expression. Harnessing T cells for cancer immunotherapy is highly topical, and has seen much recent success [1] . One promising approach involves the transfer of tumour-specific T cell receptors (TCRs) into patient T cells to redirect them into killing cancer cells prior to adoptive transfer [2, 3] . A potential limitation of this approach is that naturally occurring tumour-specific T cells tend to have low sensitivity for cognate peptide antigen as a result of bearing TCRs with weaker binding affinity than those used to recognize pathogen-derived peptides [4, 5] . As a result, there is much interest in enhancing the affinity of cancer-specific TCRs in order to optimize their sensitivity for therapeutic use. Several studies have shown that the use of enhanced-affinity TCRs can improve the recognition of tumour cells and optimized receptors for the HLA A*0201 (HLA A2)-restricted NY-ESO-1 [157] [158] [159] [160] [161] [162] [163] [164] [165] and HLA A*0101 (HLA A1)-restricted MageA3 161-169 systems have been trialled in patients [6] [7] [8] [9] [10] [11] [12] . To date, most work has focused on CD8 1 T cells due to their capacity to directly destroy tumour cells. Nevertheless, it is believed widely that tumour-specific CD4 1 T cells also play a vital role in anti-cancer immunity. Having a predominately T helper type 1 (Th1) cytokine phenotype, tumour-specific CD4 1 T cells may provide help in the proliferation, differentiation and maintenance of CD8 1 T cells in the tumour microenvironment and act in synergy with local CD8 1 T cells to control tumour growth, even though they may not necessarily have direct cytotoxic abilities [13] [14] [15] [16] . It is also possible that tumour-specific CD4 tumour-specific CD4 1 T cell help. Hence, an attractive solution to this problem would be to engineer CD4 1 T cells so that they can recognize HLA-I restricted cancer peptides and provide help directly at the tumour site. Such HLA-I redirected CD4 1 T cells have been shown to perform a variety of effector functions, including potent cytokine production and tumour cell lysis [17] [18] [19] [20] [21] [22] [23] . However, the CD8 co-receptor, absent in CD4 1 T cells, is known to provide important roles in T cell activation by stabilizing interactions of HLA-I with the TCR and optimizing TCRmediated signalling via delivery of the protein tyrosine kinase Lck to the intracellular side of the TCR-CD3 complex [24] [25] [26] . This lack of adaptation of CD4 1 T cells for recognition of HLA-I might mean that the optimal affinity and/or dwell time of HLA-I-restricted TCRs might differ when they are expressed in CD4 1 and CD8 1 T cells. We have demonstrated previously that CD8 controls T cell cross-reactivity towards HLA-I-restricted peptides [27] . Interaction of CD8 with MHC stabilizes the TCR-peptide major histocompatibility complex (pMHC) interaction [26] , thereby allowing weaker ligands to be recognized. CD8 also recruits the key kinase Lck to the cytoplasmic side of the TCR-CD3 complex and is critical to functional signalling by weaker ligands [24] . These two functions combine to allow many more ligands to be recognized in the presence of CD8 [27] . The greater cross-reactivity of HLA-I-restricted TCRs in the presence of CD8 suggests that there may be more opportunity to enhance the affinity of such TCRs in CD4 1 T cells before off-target effects are observed due to cross-recognition of self-peptides [27] . In support of this notion, experiments in the murine 2C TCR model system comparing TCRs of two distinct affinities, CD4 1 T cells expressing an MHC class I-restricted TCR with a 1000-fold higher affinity (m33 TCR, K D 5 30 nM) than the wild-type (wt) 2C TCR (K D 5 30 lM), were found to control tumour growth and persisted for longer periods in the mice, compared to similarly transduced CD8 1 T cells, which were deleted in vivo soon after transfer [28, 29] . In the human HLA A2-restricted NY-ESO-1 157-165 tumour system, transduced CD8 1 T cells expressing TCRs with a binding dissociation constant (K D ) of 84 nM were found to be cross-reactive, while transduced CD4 1 T cells only displayed off-target effects at considerably higher affinities [30] . In this study we evaluated formally the optimal binding affinity of HLA-I-restricted TCRs in CD4 1 and CD8 1 T cells by using a range of high-affinity TCRs specific for two well-studied and therapeutically important HLA A2-restricted tumour antigens, NY-ESO-1 157-165 and gp100 [280] [281] [282] [283] [284] [285] [286] [287] [288] . Our results confirm that the TCR affinity required for optimal CD4 1 T cell effector function is higher than that required for CD8 1 T cells, and show that CD4 1 T cells expressing higher-affinity TCRs displayed potent effector function.
Materials and methods
Peptides
All peptides were purchased from PeptideSynthetics (Peptide Protein Research Ltd, Bishops Waltham, UK) in lysophilized form and reconstituted in dimethylsulphoxide (DMSO) (Sigma-Aldrich, Poole, UK) to a stock solution of 4 mg/ml in DMSO and divided into aliquots such that the number of freeze-thaw cycles was kept to a minimum. Working concentrations of peptides were made in RPMI supplemented with 100 U/ml penicillin (Life Technologies, Paisley, UK), 100 lg/ml streptomycin (Invitrogen, UK) and 2 mM L-glutamine (Life Technologies). The peptides used in activation assays were SLLMWITQC (SLL, NY-ESO-1 157-165 epitope) and heteroclitic peptide YLEPGPVTV (YLE, gp100 280-288 epitope). [280] [281] [282] [283] [284] [285] [286] [287] [288] were generated in this study or as described previously [9, 30, 34] . The panel of TCR lentiviral constructs and their biophysical data are presented in Table 1 . The lentiviral transduction system utilized in these Anti-tumour HLA I-restricted CD4 1 T cells studies was kindly provided by James L. Riley (University of Pennsylvania, USA) and was described previously [9] . Briefly, lentiviral vector plasmids bearing each TCR construct were combined with packaging plasmids pRSV.REV, pMDLg/pRRE and pVSG-V before transfection of 293T/17 cells (ATCC, Manassas, VA, USA) using the Express-in transfection reagent (Open Biosystems, Huntsville, AL, USA). Supernatant containing lentiviral particles was collected after 24-and 48-h incubations and concentrated by ultracentrifugation. Activated primary CD4 1 and CD8 1 T cells (10 6 in 1 ml) were transduced with 1 ml concentrated lentivirus. Following 3 days' incubation, the efficiency of transduction was determined by flow cytometry after staining with relevant tetramer and aVb TCR antibody, and Dynabeads were removed by magnet on day 5 following transduction.
T cells and target cell lines
Measurement of soluble factors by enzyme-linked immunosorbent assay (ELISA)
T cells were resuspended at 10 6 /ml in RPMI supplemented with penicillin, streptomycin, L-glutamine and 2% FCS (R2 media) overnight. Target cells were pulsed with peptide for 1 h and washed to remove unbound peptide before T cells were added at an effector : target ratio of 1:2. After overnight incubation, tissue culture plates were centrifuged briefly to pellet cells, and the culture supernatant was harvested for measurement of lymphokines macrophage inflammatory protein (MIP)21b, interferon (IFN)-g, tumour necrosis factor (TNF)-a and IL-2 by ELISA, performed according to the manufacturer's protocol (R&D Systems, Weisbaden, Germany).
Monoclonal antibodies, amine reactive dyes and tetrameric complexes
Directly conjugated monoclonal antibodies were obtained as follows: (i) aMIP-1b-phycoerythrin (PE), aCD107a-PE and aCD69-PE (BD Biosciences, Oxford, UK); (ii) aTCR Vb 13.1-fluorescein isothiocyanate (FITC) and aTCR Vb 17-FITC (Beckman Coulter, High Wycombe, UK); (iii) live/dead fixable Aqua dead stain (Molecular Probes, Invitrogen, UK); (iv) aCD3-Pacific blue, aCD3-PEcyanin 7 (Cy7), aCD4-allophycocyanin (APC) H7, aCD8-APC H7, aCD19-Brilliant Violet 521, aIFN-g-PECy7, aTNF-aPerCPCy5.5, aIL2-APC, aperforin-Brilliant Violet 421 (clone D48) and agranzyme B-AlexFlour 647 (Biolegend, London, UK); and (v) aCD3-PCP (Miltenyi Biotech). Soluble peptide-MHCI (pMHCI) monomers were generated and biotinylated as described previously [26, 35] and tetramers for SLLMWITQC/HLA A2 and YLEPGPVTV/ HLA A2 were produced by adding streptavidin conjugated with APC (Molecular Probes, Invitrogen) [35] . The HLA type of lymphocytes isolated from blood bags was determined using directly conjugated aHLA A2-FITC (Serotec, Oxford, UK).
Intracellular cytokine staining
T cells were resuspended at 10 6 /ml in R2 media overnight. Target cells were pulsed with peptide for 1 h and washed to 
Degranulation assay
T cells were resuspended at 10 6 /ml in R2 media overnight. T2 target cells were pulsed with peptide for 1 h and washed to remove unbound peptide before adding T cell effectors at an effector : target ratio of 1:2 together with 1 ll/ml brefeldin A (Sigma-Aldrich), 0.35 ll/ml monensin (BD Biosciences) and 10 ll/ml aCD107a-PE. After 5 h of antigen stimulation, cells were washed and stained sequentially with the Aqua live/dead stain to exclude dead cells and then with antibodies for surface molecules (CD3 and CD19). Cells were fixed and permeabilized using the BD Cytofix/Cytoperm kit and stained intracellularly for CD4 or CD8, TCR-Vb, granzyme B and perforin. Stained cells were acquired and analysed as described above. 
Results
Redirecting primary CD4 1 T cells with enhanced affinity HLA-I-restricted tumour-specific TCRs Primary HLA A2
1 CD4 1 and CD8 1 T cells were transduced with lentiviruses expressing the wild-type and enhanced affinity HLA-I-restricted NY-ESO-1 and gp100 TCRs listed in Table 1. CD8 1 T cells expressing the extremely high-affinity NY-ESO-1 c58/c61 TCR (K D 5 26 pM) were not viable in culture and could not be studied, in contrast to the CD4 1 T cells transduced with the same high-affinity TCR. This is attributed probably to fratricide, as described previously [9] . CD8 1 and CD4 1 T cells transduced with two gp100-specific TCRs (wt/G2I, K D 5 402 nM; and wt/T3V, K D 5 26 nM) could not be stained with Vb17 antibody, due probably to the location of the TCR mutations (Fig. 1 ). They were hence excluded from our study, as the lack of antibody staining made it difficult to assess the expression levels of wt/G2I and wt/T3V TCRs in functional assays.
Primary CD4 1 and CD8 1 T cells transduced with all TCRs studied were stained with cognate pMHCI tetramer and antibody specific for the relevant TCR-Vb chain (Fig.  1) . Apart from wt/G2I and wt/T3V TCRs from the gp100 panel, all cells stained with the relevant TCR-Vb antibody following transduction; staining levels in the NY-ESO-1 system varied between 24-50% and 9-37% in the gp100 system. CD8
1 T cells transduced with all NY-ESO-1 TCRs including the wild-type TCR could be stained with cognate SLLMWITQC/HLA A2 tetramers. In contrast, only CD4 1 T cells with the wt/c51 and c58/c61 TCRs (K D s 5 25 nM and 26 pM, respectively) could be stained with these reagents (Fig. 1a) . Similar results were observed with the T cells transduced with gp100 TCRs, except that here CD8 1 T cells with affinities lower than 2.6 lM (wt/FGA TCR) did not stain well with cognate YLEPGPVTV/HLA A2 tetramer (Fig. 1b) . As with the NY-ESO-1 TCRs, only the CD4 1 T cells expressing high-affinity gp100 TCRs (wt/G2I, wt/G4N and wt/T3V) stained with gp100 tetramer. These results serve to highlight the important role that the CD8 co-receptor plays in pMHCI multimer binding [26, 36] . (Fig. 2) . Figure 2a shows effector function responses for cells transduced with NY-ESO-1 TCRs in the form of pie charts, as described previously [9] . CD8 1 T cells transduced with the second highest-affinity TCR (wt/c51; K D 5 25 nM) failed to respond well to 10 27 M cognate peptide, suggesting that this TCR was beyond optimal in this system, as noted previously [9] . Simultaneous direct comparison with CD4 1 T cells from the same individual showed some contrasting results, as CD4 1 T cells expressing the c58/c61 TCR were viable. However, these cells responded to T2 targets in the absence of exogenous peptide, suggesting that they were able to see a self-peptide in the context of HLA A2. Furthermore, CD4 1 T cells transduced with the wild-type NY-ESO-1 TCR failed to respond to target cells pulsed with 100 nM cognate peptide, highlighting the importance of the CD8 co-receptor with natural-affinity HLA-I-restricted TCRs as previously reported in the murine system [37] . Results with CD4 1 and CD8 1 T cells transduced with the gp100 TCRs were similar, but more exaggerated (Fig. 2b) T cells with the NY-ESO-1 system. Similarly, the optimalaffinity gp100 TCR was higher in CD4 1 T cells (wt/G4N;
Importantly, the natural-affinity TCR was suboptimal in both systems and with all effector readouts. MIP-1b was the most sensitive readout for CD8 1 T cells with both TCRs in accordance with our previous studies, showing that this b-chemokine provides the most sensitive readout for a wide range of CD8 1 T cell clones [38] [39] [40] . Indeed, background MIP-1b production was observed with the wt/ c51 TCR even in the absence of cognate peptide. Unexpectedly, MIP-1b was also the most sensitive readout for bulk CD4 HLA-I-redirected CD4 1 T cells with enhanced TCRs exhibit efficient target lysis antigen-bearing targets to that of CD8 1 T cells (Fig. 4) . As expected, transduced CD8 1 T cells proved to be efficient killers of T2 targets pulsed with both cognate antigens. NY-ESO-1 TCR-transduced CD4 1 T cells could also lyse target cells, but they required a higher affinity TCR than was necessary for CD8 1 T cell mediated lysis. The maximal specific lysis of 50% observed with NY-ESO-1 TCR-transduced CD4 1 T cells was lower than the 90% maximum seen with the wild-type TCR in CD8 1 cells. Our findings were similar in the gp100 system, although here, CD4 1 T cells transduced with the highest-affinity wt/G4N TCR tested (K D 5 35 nM) were almost as efficient at lysing targets as similarly transduced bulk CD8 1 T cells.
HLA-I-redirected CD4 1 T cells with enhanced TCRs express granzyme B and perforin and degranulate in response to cognate antigen
Observations that engineered HLA-I-restricted CD4
1 T cells could directly kill peptide-pulsed or tumour targets . The biophysical data of the higher-affinity TCRs are described in Table 1 . Values reflected here are from a single representative experiment of two independently performed experiments. UNT 5 non-transduced cells. have been reported previously, but the mechanism of target cell killing varies across studies [17] [18] [19] 21, 41] . Hence, we next compared the mechanisms that HLA-I-redirected CD4 1 and CD8 1 T cells might be use to lyse target cells and examined the expression of CD107a, granzyme B and perforin in the transduced CD4 1 and CD8 1 T cells to determine whether the observed target cell killing could be mediated by lytic granule formation. We observed distinct and marked degranulation upon peptide activation for both the NY-ESO-1 and gp100 TCR-transduced CD8 1 T cells, as inferred by increased expression of CD107a (Fig.  5) . Granzyme B production was also increased upon Anti-tumour HLA I-restricted CD4 1 T cells 
Discussion
The use of affinity-enhanced TCRs in adoptive cell transfer for cancer immunotherapy is proving promising in the clinic [42] [43] [44] . Much attention has been focused upon tumour-specific CD8
1 T cells, due to the fact that they have the potential to directly kill tumour cells. However, it is recognized increasingly that tumour-specific CD4 1 T cells also play an instrumental role in tumour control. Several obstacles preclude easy exploitation of natural tumour-specific HLA-II-restricted CD4 1 T cells. First, such cells are typically present at very low frequency. Secondly, they tend to express relatively low-affinity TCRs compared to anti-pathogen TCRs, rendering them less sensitive to cognate antigen [5] . Thirdly, very few natural tumour-specific HLA-II-restricted peptide antigens have been defined. Finally, most tumours express HLA-II poorly or not at all, thus limiting the potential for direct help at the tumour site. In addition, unlike tumourspecific CD8
1 T cells, anti-tumour CD4 1 T cells may lack direct cytotoxic abilities [16] . In order to overcome these limitations, HLA-I-restricted tumour TCRs, usually of native affinity, have been expressed on CD4
1 T cells such that they can be redirected to recognize HLA-I-restricted tumour antigens and contribute to the anti-tumour immunity [17] [18] [19] [20] [21] .
Here, we evaluated the impact of expressing a range of HLA-I-restricted tumour-specific TCRs with different affinities for cognate antigen on CD4
1 T cells and compared the functional efficacy of these redirected CD4
1 T cells with CD8 1 T cells expressing the same TCRs. Using two well-studied HLA A2-restricted tumour systems, CD4 1 T cells transduced with enhanced affinity TCRs were shown to be potent effector cells in response to cognate antigen and exhibited direct tumour lysis.
There is much support in the literature for the synergistic effects of tumour-specific CD4 1 and CD8 1 T cells within the cancer microenvironment [12, 14, 16, 17] . In our study, polyclonal CD4 1 primary T cells expressing highaffinity HLA-I-restricted NY-ESO-1 and gp100-specific TCRs produce high levels of TNF-a and IL-2. These cytokines were produced in low abundance by similarly transduced CD8 1 T cells from the same individual(s). This finding is consistent with other studies showing that CD4 1 T cells redirected to HLA-I-restricted tumour antigens produced more IL-2 compared to transduced CD8 1 T cells [19, 22] . Indeed, others have reported that paracrine cytokine production can enhance the anti-tumour functions of native or even high-affinity CD8 1 T cells by increasing CD8
1 T cell accumulation at the tumour site, increasing CD8 1 T cell tumour killing (e.g. by up-regulation of granzyme and perforin) and CD8
1 T cell proliferation [12, 14, 16, 17] . Additional IFN-g release from CD4
1 T cells may also up-regulate HLA-I and HLA-II molecules on the tumour cell surface, which may result in the recruitment of more tumour-specific CD8 1 and CD4 1 T cells to the disease site [45, 46] .
Our data show that, in general, HLA-I-redirected CD4 T cells were also less sensitive to peptide than CD8 1 T cells [22, 23] . Both these studies found that the sensitivity of transduced CD4
1 T cells could be restored when the CD8 molecule was also transferred. Our results suggest that transduction of CD4 1 T cells with enhanced-affinity TCRs can largely bypass the need for the CD8 co-receptor. These findings are supported by those of Chhabra et al., who expressed a high-affinity HLA-I-restricted MART1 TCR (K D in the nM range) on CD4
1 T cells and reported that the transduced CD4 1 T cells were as sensitive as CD8 1 T cells in producing IFN-g in the presence of peptide-pulsed targets [21] . Also, co-transfer of the CD8 molecule to CD4 1 T cells expressing high-affinity HLA-I-restricted TCRs has been shown to confer cross-reactivity to self [30] . In combination, the data to date suggest that HLA-Irestricted TCRs require different affinities and/or dwell times for optimal function in CD4
1 T cells compared to CD8 1 T cells. In conclusion, we report that polyfunctional cytotoxic anti-tumour CD4 1 T cells can be generated through the transfer of enhanced affinity TCRs specific for HLA-Irestricted tumour antigens. The TCR affinity required for the optimal anti-tumour functionality of CD4 1 T cells is higher than that required for CD8 1 T cells. CD4 1 T cells redirected to recognize HLA-I-restricted antigens with optimal TCRs can respond to low peptide densities, making them attractive for immunotherapy, as tumourassociated peptides are usually present at the cell surface at very low copy numbers of fewer than 50 copies per cell ( [47] 
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